

CLAIMS

- 1.- Use of 2,5-dihydroxybenzenesulfonic acid or of any of its pharmaceutically acceptable salts for the manufacture of medicines applicable to the treatment of angiodependent diseases.
- 2.- Use according to claim 1 wherein the angiodependent disease also presents a reduction of apoptosis.
- 3.- Use according to any of claims 1 or 2 wherein the manufactured medicine is for application in the treatment of cancer.
- 4.- Use according to claim 3 characterized in that the manufactured medicine is used to increase the antiproliferative effect of cytostatic medicines in the treatment of cancer.
- 5.- Use according to any of claims 1 to 4 characterized in that the salt preferred for the manufacture of the medicine is the potassium salt of 2,5-dihydroxybenzene sulfonic acid.
- 6.- Use according to any of the claims 1 to 4 characterized in that the salt preferred for the manufacture of the medicine is the calcium salt of 2,5-dihydroxybenzene sulfonic acid.
- 7.- Use according to any of claims 1 to 6 wherein the manufactured medicine also includes an adequate amount of at least one pharmaceutically acceptable excipient.
- 8.- Use according to claim 1 wherein the manufactured medicine is for application in the treatment of psoriasis.
- 9.- Use according to claim 8 characterized in that the salt preferred for the manufacture of the medicine is the potassium salt of 2,5-dihydroxybenzenesulfonic acid.

10. Use according to claim 8, characterized in that the salt preferred for the manufacture of the medicine is the calcium salt of 2,5-dihydroxybenzenesulfonic acid.
11. Use according to any of claims 8 to 10 wherein the manufactured medicine also includes adequate amount of at least one pharmaceutically acceptable excipient.
- 5 12.- Use according to any of the claims 8 to 11 characterized in that the medicine is a topical application formulation.
- 13.- Use according to claim 12 characterized in that the medicine is a cream or unguent whose composition includes:
 - 10 • a pharmaceutically efficient amount of 2,5-dihydroxybenzenesulfonic acid or of any of its pharmaceutically acceptable salts
 - a pharmaceutically acceptable amount of at least one alcohol
 - a pharmaceutically acceptable amount of at least one emulsifier
 - a pharmaceutically acceptable amount of at least one excipient which forms a lipidic phase, particularly vaseline
 - 15 • distilled water
- 14.- Use according to claim 13 characterized in that the medicine is a cream or unguent that presents a composition that includes:
 - 5% of the potassium salt of 2,5-dihydroxybenzenesulfonic acid
 - 2,5% of cetylic alcohol
 - 20 • 2,5% of stearic alcohol
 - 30% of liquid vaseline
 - 20% of white soft paraffin

- 5% span (sorbitan oleate)
- q.s 100 g of distilled water